ARS Pharmaceuticals (SPRY) Net Cash Flow (2020 - 2026)

ARS Pharmaceuticals has disclosed Net Cash Flow across 7 years of filings, most recently posting -$17.0 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$17.0 million, down 55.17% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.5 million (up 3.71% YoY), and the FY2025 annual result was -$9.5 million, up 52.86% from the prior year.
• Net Cash Flow came in at -$17.0 million for Q1 2026 at ARS Pharmaceuticals, up from -$18.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $173.2 million in Q4 2022 to a low of -$122.7 million in Q1 2023.
• The 5-year median for Net Cash Flow is -$7.6 million (2022), against an average of -$2.1 million.
• Peak annual rise in Net Cash Flow reached 508.91% in 2023, while the deepest fall reached 1461.7% in 2023.
• ARS Pharmaceuticals' Net Cash Flow stood at $173.2 million in 2022, then tumbled by 93.97% to $10.4 million in 2023, then gained by 6.91% to $11.2 million in 2024, then sank by 263.44% to -$18.2 million in 2025, then climbed by 6.82% to -$17.0 million in 2026.
• The last three Net Cash Flow figures came in at -$17.0 million (Q1 2026), -$18.2 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.